Evidence map›Paper›PMID 42547548›Full record

ReviewNature reviews. Neurology2026

Towards a biologically informed description of multiple sclerosis disease course - a roadmap for transition.

Alan J Thompson, Fred D Lublin, Lindsay Rechtman, James Quinn, Maria Pia Amato, Bruce Bebo, Peter A Calabresi, Julie Fiol, Marcia Finlayson, Annie Hawton and 11 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Alan J ThompsonQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, NIHR University College London Hospitals Biomedical Research Centre, Faculty of Brain Sciences, University College London, London, UK. alan.thompson@ucl.ac.uk.ORCID http://orcid.org/0000-0002-4333-8496
Fred D LublinThe Corinne Goldsmith Dickinson Center for MS, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. fred.lublin@mssm.edu.ORCID http://orcid.org/0000-0001-5722-0475
Lindsay RechtmanNational Multiple Sclerosis Society, New York, NY, USA.ORCID http://orcid.org/0009-0000-4059-9108
James QuinnNational Multiple Sclerosis Society, New York, NY, USA.
Maria Pia AmatoDepartment NEUROFARBA, University of Florence, IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.ORCID http://orcid.org/0000-0003-3325-3760
Bruce BeboNational Multiple Sclerosis Society, New York, NY, USA.ORCID http://orcid.org/0000-0003-0941-9169
Peter A CalabresiDepartment of Neurology, The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-7776-6472
Julie FiolNational Multiple Sclerosis Society, New York, NY, USA.ORCID http://orcid.org/0009-0001-0109-7698
Marcia FinlaysonSchool of Rehabilitation Therapy, Queens University, Kingston, Ontario, Canada.ORCID http://orcid.org/0000-0002-1774-4810
Annie HawtonUniversity of Exeter Medical School, University of Exeter, Exeter, UK.ORCID http://orcid.org/0000-0002-1336-5899
Tanja KuhlmannInstitute for Neuropathologie, University of Munster, Munster, Germany.ORCID http://orcid.org/0000-0002-0174-5042
Ruth Ann MarrieDepartment of Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Marcello MocciaQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, NIHR University College London Hospitals Biomedical Research Centre, Faculty of Brain Sciences, University College London, London, UK.
Xavier MontalbanMultiple Sclerosis Centre of Catalonia, Barcelona, Spain.
Michael PanzaraImmunic Therapeutics, New York, NY, USA.
Kathy SmithKES Consulting, Lyme, CT, USA.ORCID http://orcid.org/0000-0001-9558-9038
Maria Pia SormaniDepartment of Health Sciences, University of Genoa, Genoa, Italy.ORCID http://orcid.org/0000-0001-6892-104X
Jon StrumReal Talk MS, Long Beach, CA, USA.
Barbara G VickreyDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Timothy CoetzeeNational Multiple Sclerosis Society, New York, NY, USA.ORCID http://orcid.org/0000-0002-3031-7549
2025 International Advisory Committee on Clinical Trials in Multiple Sclerosis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing-remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the multiple sclerosis disease course.

Indexed as

Disease ProgressionMultiple SclerosisHumans

Identifiers

PMID42547548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.